2025
Impact of Tumor Stage on Oncologic Outcomes of High-grade Bacillus Calmette-Guérin Unresponsive Non–muscle-invasive Bladder Cancer Undergoing Bladder-sparing Therapies
Annapureddy D, Taylor J, Kamat A, O'Donnell M, Howard J, Tan W, McElree I, Davaro F, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, Woldu S, Lotan Y. Impact of Tumor Stage on Oncologic Outcomes of High-grade Bacillus Calmette-Guérin Unresponsive Non–muscle-invasive Bladder Cancer Undergoing Bladder-sparing Therapies. European Urology Focus 2025 PMID: 39922753, DOI: 10.1016/j.euf.2025.01.001.Peer-Reviewed Original ResearchNon-muscle-invasive bladder cancerCarcinoma in situBCG-unresponsive NMIBCBladder-sparing therapyOncological outcomesTumor stageBladder cancer mortalityCancer mortalityAssociated with worse oncologic outcomesPresence of carcinoma in situCarcinoma in situ groupImpact of tumor stageTA groupKaplan-Meier methodPapillary diseaseT1 diseaseRadical cystectomyNo significant differenceClinical stageBladder cancerSurvival differencesRetrospective natureCis groupDisease progressionMetastasisSurgical Management of Breast Cancer Liver Metastasis
Rahnemai-Azar A, Selby L, Lustberg M, Pawlik T. Surgical Management of Breast Cancer Liver Metastasis. Hematology/Oncology Clinics Of North America 2025, 39: 25-35. PMID: 39510675, DOI: 10.1016/j.hoc.2024.08.012.Peer-Reviewed Original ResearchConceptsBreast cancer liver metastasesSystemic chemotherapyHepatic resectionAblation therapyIsolated breast cancer liver metastasesLong-term outcomes of womenProlonged disease-free intervalLocal-regional therapyCancer liver metastasesDisease-free intervalOutcomes of womenBreast cancer metastasisLong-term outcomesRegional therapyLiver metastasesOverall survivalSurgery benefitMultidisciplinary settingCancer metastasisPatientsResectionChemotherapyMetastasisTherapySurgerySacral tumors: a comprehensive review of imaging, diagnostic challenges, and tumor mimics
Adin M, Woolf G, Hegde R, Elsamadicy A, Mendel E, Zucconi W, Pucar D, Aygün N. Sacral tumors: a comprehensive review of imaging, diagnostic challenges, and tumor mimics. Skeletal Radiology 2025, 1-26. PMID: 39821683, DOI: 10.1007/s00256-024-04862-6.Peer-Reviewed Original ResearchPrimary tumorTumor mimicsImaging findingsAssessment of response to treatmentGerm cell tumorsEvaluation of systemic diseasesResponse to treatmentInsufficiency fracturesSacral massSecondary tumorsCell tumorsPretreatment evaluationDiagnostic challengeLymphoproliferative diseaseClinical detailsMalignant tumorsPrimary modalitySystemic diseaseEwing sarcomaTumorNotochordal remnantsDevelopmental entityEpidemiological factorsDiagnosisMetastasisDermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology.
Bordeaux J, Blitzblau R, Aasi S, Alam M, Amini A, Bibee K, Bolotin D, Chen P, Contreras C, DiMaio D, Donigan J, Farma J, Ghosh K, Harms K, LeBoeuf N, Lukens J, Manber S, Mark L, Medina T, Nehal K, Nghiem P, Olino K, Paragh G, Park S, Patel T, Rich J, Shaha A, Sharma B, Sokumbi Y, Srivastava D, Thomas V, Tomblinson C, Venkat P, Xu Y, Yu S, Yusuf M, McCullough B, Espinosa S. Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology. Journal Of The National Comprehensive Cancer Network 2025, 23 PMID: 39819674, DOI: 10.6004/jnccn.2025.0001.Peer-Reviewed Original ResearchConceptsNCCN Clinical Practice GuidelinesDermatofibrosarcoma protuberansClinical practice guidelinesNegative marginsFibrosarcomatous dermatofibrosarcoma protuberansRate of recurrenceSoft tissue sarcomasRecommended treatment optionPractice guidelinesCutaneous soft tissue sarcomasLocal recurrenceRadiation therapySurgical excisionAggressive variantSystemic treatmentInitial treatmentTissue sarcomasTreatment optionsLocal infiltrationIncreased riskRecurrenceMetastasisProtuberansMultidisciplinary teamNCCN
2024
Modeling lung adenocarcinoma metastases using patient-derived organoids
Liu Y, Lankadasari M, Rosiene J, Johnson K, Zhou J, Bapat S, Chow-Tsang L, Tian H, Mastrogiacomo B, He D, Connolly J, Lengel H, Caso R, Dunne E, Fick C, Rocco G, Sihag S, Isbell J, Bott M, Li B, Lito P, Brennan C, Bilsky M, Rekhtman N, Adusumilli P, Mayo M, Imielinski M, Jones D. Modeling lung adenocarcinoma metastases using patient-derived organoids. Cell Reports Medicine 2024, 5: 101777. PMID: 39413736, PMCID: PMC11513837, DOI: 10.1016/j.xcrm.2024.101777.Peer-Reviewed Original ResearchConceptsMetastasis modelLung adenocarcinomaAutologous peripheral blood mononuclear cellsEarly-stage lung cancerMechanisms of drug resistancePeripheral blood mononuclear cellsBlood mononuclear cellsEfficacy of treatmentLung cancer metastasisLung adenocarcinoma metastasisDistant metastasisStudy clonalityAdenocarcinoma metastasisLung cancerMononuclear cellsDrug resistanceMetastasisSuppress metastasisIndividual patientsTumor evolutionCancer metastasisHuman metastasesPatientsBiological featuresRNA sequencingMapping extrachromosomal DNA amplifications during cancer progression
Kim H, Kim S, Wade T, Yeo E, Lipsa A, Golebiewska A, Johnson K, An S, Ko J, Nam Y, Lee H, Kang S, Chung H, Niclou S, Moon H, Paek S, Bafna V, Luebeck J, Verhaak R. Mapping extrachromosomal DNA amplifications during cancer progression. Nature Genetics 2024, 56: 2447-2454. PMID: 39402156, PMCID: PMC11549044, DOI: 10.1038/s41588-024-01949-7.Peer-Reviewed Original ResearchConceptsPretreatment tumorsCancer progressionChemotherapy-pretreated patientsNewly diagnosed tumorsVariant allele fractionUntreated metastasesPrimary cancerUntreated cancerTreatment responseFocal amplificationTumor samplesChromosomal amplificationsDiagnosed cancerTumorExtrachromosomal DNA amplificationsAdvanced cancerCancerEcDNATime pointsMetastasisNewlyDNA amplificationProgressionExtrachromosomal DNAPatientsMetFinder: A Tool for Automated Quantitation of Metastatic Burden in Histological Sections From Preclinical Models
Karz A, Coudray N, Bayraktar E, Galbraith K, Jour G, Shadaloey A, Eskow N, Rubanov A, Navarro M, Moubarak R, Baptiste G, Levinson G, Mezzano V, Alu M, Loomis C, Lima D, Rubens A, Jilaveanu L, Tsirigos A, Hernando E. MetFinder: A Tool for Automated Quantitation of Metastatic Burden in Histological Sections From Preclinical Models. Pigment Cell & Melanoma Research 2024, 38: e13195. PMID: 39254030, DOI: 10.1111/pcmr.13195.Peer-Reviewed Original ResearchTumor contentMetastasis burdenMetastatic burdenTumor burdenMelanoma metastasesPreclinical modelsMurine modelPreclinical studiesMeasurable metastasesMelanoma researchTherapeutic approachesDeep neural networksHistopathological sectionsMechanisms of melanoma metastasisMetastasisHistological sectionsAI-based algorithmsAutomated quantificationWhole slide imagesAutomated quantitationNeural networkOutcomes of repeat conventional transarterial chemoembolization in patients with liver metastases
Ghabili K, Windham-Herman A, Konstantinidis M, Murali N, Borde T, Adam L, Laage-Gaupp F, Lin M, Chapiro J, Georgiades C, Nezami N. Outcomes of repeat conventional transarterial chemoembolization in patients with liver metastases. Annals Of Hepatology 2024, 29: 101529. PMID: 39033928, PMCID: PMC11558520, DOI: 10.1016/j.aohep.2024.101529.Peer-Reviewed Original ResearchConventional transarterial chemoembolizationLiver metastasesNeuroendocrine tumorsColorectal carcinomaTransarterial chemoembolizationOverall survivalLung cancerAssociated with improved patient survivalManagement of liver metastasesMetastatic liver lesionsSingle-institution analysisNonresponding patientsSurvival outcomesPatient survivalResponse assessmentTarget lesionsMetastasisLiver lesionsPatientsResponse rateChemoembolizationSurvivalLiverLesionsCancerOverexpression of Malat1 drives metastasis through inflammatory reprogramming of the tumor microenvironment
Martinez-Terroba E, Plasek-Hegde L, Chiotakakos I, Li V, de Miguel F, Robles-Oteiza C, Tyagi A, Politi K, Zamudio J, Dimitrova N. Overexpression of Malat1 drives metastasis through inflammatory reprogramming of the tumor microenvironment. Science Immunology 2024, 9: eadh5462. PMID: 38875320, DOI: 10.1126/sciimmunol.adh5462.Peer-Reviewed Original ResearchConceptsTumor microenvironmentLung adenocarcinomaMetastatic diseasePromoting metastatic diseaseGlobal chromatin accessibilityMetastasis-associated lung adenocarcinoma transcript 1Overexpression of MALAT1Lung adenocarcinoma transcript 1Lung adenocarcinoma metastasisCCL2 blockadeInflammatory reprogrammingEnhanced cell mobilityMacrophage depletionMechanism of actionTumor typesTumor progressionMouse modelCell mobilizationTumorLong noncoding RNAsParacrine secretionMetastasisCell linesTranscript 1MicroenvironmentNavigating the Complexities of Brain Metastases Management.
Amouzegar A, Haig S, Kahn A, Tawbi H, Jones J, Goldberg S. Navigating the Complexities of Brain Metastases Management. American Society Of Clinical Oncology Educational Book 2024, 44: e433694. PMID: 38781565, DOI: 10.1200/edbk_433694.Peer-Reviewed Original ResearchConceptsBrain metastasesSystemic therapySolid tumorsIncidence of brain metastasesManagement of brain metastasesEfficacy of systemic therapyBrain metastasis managementMetastatic solid tumorsComplication of advanced cancerExclusion of patientsEnhanced imaging technologiesMetastasis managementSystemic treatmentTargeted therapyBreast cancerExtended survivalClinical dataClinical trialsMetastasisAdvanced cancerTherapyEarly detectionTumorPatientsCancerEBUS-TBNA pleural biopsy reveals prostate cancer metastasis: A rare case report and review of the literature
Sampsonas F, Komninos D, Sotiropoulou V, Katsaras M, Gkanetsou D, Papaioannou O, Tsiri P, Tzelepi V, Tzouvelekis A. EBUS-TBNA pleural biopsy reveals prostate cancer metastasis: A rare case report and review of the literature. Pneumon 2024, 37: 1-4. DOI: 10.18332/pne/188870.Peer-Reviewed Original ResearchArtificial Intelligence Helps Pathologists Increase Diagnostic Accuracy and Efficiency in the Detection of Breast Cancer Lymph Node Metastases
Retamero J, Gulturk E, Bozkurt A, Liu S, Gorgan M, Moral L, Horton M, Parke A, Malfroid K, Sue J, Rothrock B, Oakley G, DeMuth G, Millar E, Fuchs T, Klimstra D. Artificial Intelligence Helps Pathologists Increase Diagnostic Accuracy and Efficiency in the Detection of Breast Cancer Lymph Node Metastases. The American Journal Of Surgical Pathology 2024, 48: 846-854. PMID: 38809272, PMCID: PMC11191045, DOI: 10.1097/pas.0000000000002248.Peer-Reviewed Original ResearchConceptsLymph node metastasisNode metastasisDetection of lymph node metastasesBreast cancer lymph node metastasisMetastasis detection rateWhole slide imagesBreast cancer stageArtificial intelligenceIncrease diagnostic accuracyReading pathologistsCancer stageDiagnostic accuracyMetastasisCancer metastasisAverage reading timeBreastPathologistsDetection rateAI algorithmsPROTAC EZH2 degrader-1 overcomes the resistance of podophyllotoxin derivatives in refractory small cell lung cancer with leptomeningeal metastasis
Shi M, Ding X, Tang L, Cao W, Su B, Zhang J. PROTAC EZH2 degrader-1 overcomes the resistance of podophyllotoxin derivatives in refractory small cell lung cancer with leptomeningeal metastasis. BMC Cancer 2024, 24: 504. PMID: 38644473, PMCID: PMC11034131, DOI: 10.1186/s12885-024-12244-3.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerCell lung cancerMouse modelLung cancerRefractory small cell lung cancerNude miceIn vivo drug testingCell linesDrug testingLM cellsSensitivity of cisplatinIn vitro drug testingIncreased in vitroBackgroundLeptomeningeal metastasisLeptomeningeal metastasesSevere neurological disordersAssociated with several neurological disordersDrug sensitivityIn vivo live imagingHistological examinationCarotid arteryEffective treatmentMetastasisDrug trialsExpressing luciferaseThe Scenic Route: Lingular Metastasectomy Through the Right Chest
Udelsman B, Blasberg J. The Scenic Route: Lingular Metastasectomy Through the Right Chest. Annals Of Thoracic Surgery Short Reports 2024, 2: 506-508. PMID: 39790420, PMCID: PMC11708399, DOI: 10.1016/j.atssr.2024.03.010.Peer-Reviewed Original ResearchRight chestMinimally invasive wedge resectionIsolated pulmonary metastasesIpsilateral chestIsolated metastasisOverall-survivalPulmonary metastasesSurgical resectionWedge resectionAnterior mediastinumThoracoscopic approachDisease-freeLeft thoracotomyResectionMetastasectomyChestMetastasisPatientsPleurodesisMediastinumThoracotomyVascular mimicry as a facilitator of melanoma brain metastasis
Provance O, Oria V, Tran T, Caulfield J, Zito C, Aguirre-Ducler A, Schalper K, Kluger H, Jilaveanu L. Vascular mimicry as a facilitator of melanoma brain metastasis. Cellular And Molecular Life Sciences 2024, 81: 188. PMID: 38635031, PMCID: PMC11026261, DOI: 10.1007/s00018-024-05217-z.Peer-Reviewed Original ResearchConceptsVascular mimicryBrain metastasesMouse model of metastatic melanomaIncreased risk of metastasisAssociated with tumor volumeMelanoma brain metastasesRisk of metastasisSurvival of miceFuture treatment regimensCell line modelsTumor suppressor pathwayMetastatic melanomaTumor volumeSolid tumorsTreatment regimensTumor typesPoor prognosisHippo tumor suppressor pathwayIncreased riskMouse modelDownstream targets YAPMelanomaMetastasisSuppressor pathwayTumorProgrammable Bacteria‐Based Biohybrids as Living Biotherapeutics for Enhanced Cancer Sonodynamic‐Immunotherapy
Wang C, Chen L, Zhu J, Wang C, Li M, Miao Y, Liu N, Ji Z, Pan F, Liu Y, Zhu J, Yang Y, Chen Q. Programmable Bacteria‐Based Biohybrids as Living Biotherapeutics for Enhanced Cancer Sonodynamic‐Immunotherapy. Advanced Functional Materials 2024, 34 DOI: 10.1002/adfm.202316092.Peer-Reviewed Original ResearchSonodynamic therapyAntitumor immune responseTumor-associated antigensImmune memory responsePrevent tumor recurrenceInhibit tumor metastasisOrthotopic colorectal tumorsAbscopal effectTumor recurrenceEffective sonodynamic therapyTumor siteNano-sonosensitizersTumor hypoxiaPathogen-associated molecular patternsColorectal tumorsMemory responsesTherapeutic delivery systemsTumor metastasisImmune responseTumorLive biotherapeuticsMetastasisBacterial pathogen-associated molecular patternsMolecular patternsOverexpressing catalaseNanomodulators targeting endothelial WNT and pericytes to reversibly open the blood–tumor barrier for boosted brain tumor therapy
Mu R, Sun H, Zeng Y, Tong Y, Tang P, Zhao M, Lv Z, Yu J, Chen Y, Lan Q, Zhen X, Han L. Nanomodulators targeting endothelial WNT and pericytes to reversibly open the blood–tumor barrier for boosted brain tumor therapy. Journal Of Controlled Release 2024, 369: 458-474. PMID: 38575077, DOI: 10.1016/j.jconrel.2024.03.047.Peer-Reviewed Original ResearchBreast cancer brain metastasesCancer brain metastasesBrain metastasesMedian survival of miceWnt signalingTumor-associated blood vesselsBlood-tumor barrierSurvival of miceBrain tumor therapyImproving chemotherapeutic efficiencyBrain-targeting drugsMedian survivalIntracranial edemaChemotherapeutic drugsICAM-1Tumor pericytesBrain entryTumor therapyChemotherapeutic efficiencyMetastasisInactivate Wnt signalingPericytesBlood vesselsIbrutinibBreastTRPM7 facilitates fibroblast-like synoviocyte proliferation, metastasis and inflammation through increasing IL-6 stability via the PKCα-HuR axis in rheumatoid arthritis
Lin Y, Chen Y, Hu W, Liu X, Hao W, Xing J, Ding J, Xu Y, Yao F, Zhao Y, Wang K, Li S, Yu Q, Hu W, Zhou R. TRPM7 facilitates fibroblast-like synoviocyte proliferation, metastasis and inflammation through increasing IL-6 stability via the PKCα-HuR axis in rheumatoid arthritis. International Immunopharmacology 2024, 132: 111933. PMID: 38581988, DOI: 10.1016/j.intimp.2024.111933.Peer-Reviewed Original ResearchConceptsTransient receptor potential melastatin 7Rheumatoid arthritisInhibition of transient receptor potential melastatin 7Human RA patientsSynovial hyperplasiaAdjuvant-induced arthritis ratsIncreased TRPM7 expressionIL-6 mRNATreatment of RAPathogenesis of RAFibroblast-like synoviocytesTRPM7 silencingProgression of rheumatoid arthritisTRPM7 expressionChannel inhibitionCation channelsRA patientsMetastasisPharmacological inhibitionArthritis ratsInflammationNuclear translocationSynoviocyte proliferationHyperplasiaProliferationPractical Considerations for the Treatment of an Adrenal Metastasis With Stereotactic Body Radiation Therapy
Yu J, Grew D, Sculley E, Hitchcock K, Kim M, Lo S. Practical Considerations for the Treatment of an Adrenal Metastasis With Stereotactic Body Radiation Therapy. Practical Radiation Oncology 2024, 14: 338-342. PMID: 38493984, DOI: 10.1016/j.prro.2024.02.003.Peer-Reviewed Original ResearchThe impact of cancer metastases on COVID‐19 outcomes: A COVID‐19 and Cancer Consortium registry‐based retrospective cohort study
Castellano C, Sun T, Ravindranathan D, Hwang C, Balanchivadze N, Singh S, Griffiths E, Puzanov I, Ruiz‐Garcia E, Vilar‐Compte D, Cárdenas‐Delgado A, McKay R, Nonato T, Ajmera A, Yu P, Nadkarni R, O’Connor T, Berg S, Ma K, Farmakiotis D, Vieira K, Arvanitis P, Saliby R, Labaki C, Zarif T, Wise‐Draper T, Zamulko O, Li N, Bodin B, Accordino M, Ingham M, Joshi M, Polimera H, Fecher L, Friese C, Yoon J, Mavromatis B, Brown J, Russell K, Nanchal R, Singh H, Tachiki L, Moria F, Nagaraj G, Cortez K, Abbasi S, Wulff‐Burchfield E, Puc M, Weissmann L, Bhatt P, Mariano M, Mishra S, Halabi S, Beeghly A, Warner J, French B, Bilen M, Consortium F. The impact of cancer metastases on COVID‐19 outcomes: A COVID‐19 and Cancer Consortium registry‐based retrospective cohort study. Cancer 2024, 130: 2191-2204. PMID: 38376917, PMCID: PMC11141719, DOI: 10.1002/cncr.35247.Peer-Reviewed Original ResearchConceptsSupplemental O<sub>2</sub>COVID-19 severityMetastatic cancerLogistic regression modelsMetastases to other sitesSite of metastatic cancerCOVID-19 outcomesMetastasis to boneRetrospective cohort studyAll-cause mortalityIntensive care unitDay mortalityLymph nodesIncreased hospitalization ratesMechanical ventilationCohort studyMetastasisCare unitPatientsCancer metastasisRegression modelsCancerSevere outcomesCancer ConsortiumOrdinal logistic regression model
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply